Roche Holding reported CHF7.55B in Cash and Equivalent for its fiscal semester ending in June of 2025.





Cash And Equivalent Change Date
AbbVie USD 10.77B 4.2B Sep/2026
Alcon AG USD 1.7B 350M Sep/2026
Almirall EUR 354.57M 16.8M Jun/2026
Amgen USD 13.19B 799M Sep/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Biogen USD 1.3B 18.9M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Fresenius EUR 1.28B 780M Jun/2026
Fresenius Medical Care EUR 1.1B 37.86M Sep/2026
Genmab DKK 1.5B 18M Jun/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
GRIFOLS EUR 486M 27M Sep/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lakefront Biotherapeutics EUR 94.66M 41.3M Sep/2026
Lonza CHF 719M 188M Dec/2025
Merck EUR 1.96B 788M Jun/2026
Merck USD 9.55B 2.7B Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Orion EUR 144.3M 55M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Philips EUR 2.75B 962M Sep/2026
Recordati EUR 391.38M 10.92M Jun/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
UCB EUR 1.57B 1.14B Dec/2024